Alicia Chionchio1, Andrew Galmer2, Benjamin Hirsh3. 1. Department of Medicine, Hofstra University School of Medicine, Northwell Health, New York, USA. 2. Department of Medicine, Division of Cardiology, Hofstra Northwell School of Medicine, 300 Community Drive, Manhasset, NY, 11030, USA. 3. Department of Medicine, Division of Cardiology, Hofstra Northwell School of Medicine, 300 Community Drive, Manhasset, NY, 11030, USA. bhirsh@northwell.edu.
Abstract
PURPOSE OF REVIEW: The diagnosis of peripheral arterial disease (PAD) is a high-risk marker for accelerated atherosclerotic cardiovascular disease (ASCVD) and is associated with substantial morbidity and mortality. In addition to common, modifiable cardiovascular disease risk factors that contribute to PAD, which include hypertension, diabetes mellitus, and smoking, an elevation in concentrations of serum atherogenic lipoproteins (lipids) is an increasingly recognized contributor to premature atherosclerosis. RECENT FINDINGS: The recognition and inclusion of PAD as a marker of higher-cardiovascular risk demonstrates the need to aggressively reduce elevations in atherogenic lipoproteins, particularly low-density-lipoprotein cholesterol. In addition to diet, lifestyle, and statin therapy, there is evidence that novel, pharmacologic lipid-lowering treatments improve specific outcomes in patients with PAD as primary and adjunctive therapy. In this review, we discuss the efficacy and evolving roles of statin and novel nonstatin therapies on outcomes in patients with PAD.
PURPOSE OF REVIEW: The diagnosis of peripheral arterial disease (PAD) is a high-risk marker for accelerated atherosclerotic cardiovascular disease (ASCVD) and is associated with substantial morbidity and mortality. In addition to common, modifiable cardiovascular disease risk factors that contribute to PAD, which include hypertension, diabetes mellitus, and smoking, an elevation in concentrations of serum atherogenic lipoproteins (lipids) is an increasingly recognized contributor to premature atherosclerosis. RECENT FINDINGS: The recognition and inclusion of PAD as a marker of higher-cardiovascular risk demonstrates the need to aggressively reduce elevations in atherogenic lipoproteins, particularly low-density-lipoprotein cholesterol. In addition to diet, lifestyle, and statin therapy, there is evidence that novel, pharmacologic lipid-lowering treatments improve specific outcomes in patients with PAD as primary and adjunctive therapy. In this review, we discuss the efficacy and evolving roles of statin and novel nonstatin therapies on outcomes in patients with PAD.
Authors: Sumeet Subherwal; Manesh R Patel; Lars Kober; Eric D Peterson; William S Jones; Gunnar H Gislason; Jeffrey Berger; Christian Torp-Pedersen; Emil L Fosbol Journal: Circulation Date: 2012-08-08 Impact factor: 29.690
Authors: Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh Journal: J Am Coll Cardiol Date: 2017-03-21 Impact factor: 24.094
Authors: Thomas F X O'Donnell; Sarah E Deery; Jeremy D Darling; Katie E Shean; Murray A Mittleman; Gabrielle N Yee; Matthew R Dernbach; Marc L Schermerhorn Journal: J Vasc Surg Date: 2017-05-12 Impact factor: 4.268
Authors: Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo Journal: JAMA Date: 2016-08-16 Impact factor: 56.272
Authors: Benjamin J Hirsh; Nathaniel R Smilowitz; Robert S Rosenson; Valentin Fuster; Laurence S Sperling Journal: J Am Coll Cardiol Date: 2015-07-14 Impact factor: 24.094
Authors: Shipra Arya; Anjali Khakharia; Zachary O Binney; Randall R DeMartino; Luke P Brewster; Philip P Goodney; Peter W F Wilson Journal: Circulation Date: 2018-01-12 Impact factor: 29.690